BioAtla announces data on Mecbotamab Vedotin

BioAtla (BCAB) announced clinical data in a poster titled “Median OS of 21.5 months among 44 patients with treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma treated with mecbotamab vedotin, an AXL-targeting ADC,” at the Society for Immunotherapy of Cancer, SITC, 2025 Annual Meeting, being held November 5-9, 2025, in National Harbor, Maryland. Mec-V demonstrates median OS of 21.5 months in patients with treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma compared with approximately 12 months with approved agents. Mec-V safety profile as monotherapy, and in combination with anti-PD-1 antibody, was manageable and consistent with conditional binding of the AXL target restricted to the tumor microenvironment.